Dabashish Patowary1, Nur-E-Jannatul Ferdous2, Biswajit Bhattacharjee3,
Tania Gaffar4, Sabina Yeasmin5, Golam Mostofa6
Tania Gaffar4, Sabina Yeasmin5, Golam Mostofa6
1. Assistant Professor, Department Of Oncology, North East Medical College & Cancer Hospital, Sylhet.
2. Assistant Professor, Department Of Pathology, North East Medical College, Sylhet.
3. Senior Consultant, Department Of Oncology, North East Medical College & Cancer Hospital, Sylhet.
4. Assistant Professor, Department Of Pathology, Uttara Adhunic Medical College, Uttara, Dhaka.
5. Lecturer, Department of Pathology, Mugda Medical College, Dhaka.
6. Department of Medicine, Combined Military Hospital (CMH), Jalalabad Cantonment, Sylhet.
Abstract
Carcinoma of the breast is the most common non-skin malignancy in women and it was the second cause of cancer deaths only to lung cancer. Recent attention has been directed singularly at molecular classifications of breast cancer. Molecular subtypes have different prognostic and therapeutic implications. The aim of this study was to assess the ER, PR, and HER-2/neu reactivity pattern in breast carcinomas and to correlate this reactivity pattern with stage tumor size and lymph node metastasis This is a prospective analytical observational study was conducted in the North East Cancer Hospital and Department of Pathology of North East Medical College, Sylhet, Bangladesh during a 42 months period from July 2015 to December 2018. Among 67 Cases of primary invasive breast carcinoma only one case was male and 66 were female. Age of our study population ranges from 26 to 85 years with the mean age 45.25 years, high incidence was observed in fourth decades. In aspect of tumor size most of the patient presented with 2-5cm tumor, 47 cases (70.2%) and (80.6%) presented with more than 2cm tumor size. In our study 56.7% (38 cases) of breast cancer found ER positive, 38.8%(26 cases) PR positive and 22.4% (15 cases) HER2/neu positive, most common presentation of the disease was at stage IIB(29 cases, 45%), lymph node positivity 46 cases (68.7%) and lymph node negative 21 cases (31.3%), 5 cases (7.5%). In aspect of molecular subtyping we found luminal A 43.3% (29 cases) Luminal B 11.9% (8 cases) basal like 32.8% (22 cases) and HER-2/neu over expressed 11.9% (8 cases), As it is a single hospital base study the North East Cancer Hospital started at 2014 and our study started July 2015 so we couldn’t follow up the patient more than two and half years. Though 5 year survival is worldwide accepted, we followed up the patients 6 month, 1 year, I and half year, 2 year 2 and half year. Out of 67 patients 17 followed up for 6 month of whose I was dead, 20 for 1 year of whose I was dead and 19 was alive, 14 for 1 and half year of whose 1 was dead and 13 was alive, 13 for 2 year of whose 4 was dead and 9 was alive, 3 for 2 and half year of whose I was dead and 2 was alive. The patients were presented in our study at later stage compare to western country. Cancer screening and early detection program can improve our scenario. In case of survival, multicentered and long term study can valided the result of our study.
Key Words: Breast carcinoma, HER-2/neu, ER/PR, Immunohistochemistry(IHC).